A common polymorphism in the tumour necrosis factor-alpha gene associated with high TNF levels is not a risk factor for venous thromboembolism

Br J Haematol. 1998 Jun;101(3):480-2. doi: 10.1046/j.1365-2141.1998.00729.x.

Abstract

The odds ratio of homozygosity or heterozygosity for the TNF2 polymorphism in 575 patients with venous thromboembolism compared to controls was found to be 1.0 (95% CI 0.4-2.1) and 1.1 (95% CI 0.8-1.4) respectively. Comparing subgroups of patients and controls with the factor V Leiden mutation the odds ratio for the TNF2 polymorphism was 0.7 (95% CI 0.2-2.2). Despite evidence of a link between high tumour necrosis factor (TNF) levels and hypercoagulability, our results do not indicate a link between the genetic regulation of TNF production and venous thromboembolic disease.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Factor V / genetics
  • Female
  • Gene Frequency
  • Heterozygote
  • Homozygote
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Polymorphism, Genetic*
  • Risk Factors
  • Thromboembolism / genetics*
  • Tumor Necrosis Factor-alpha / genetics*

Substances

  • Tumor Necrosis Factor-alpha
  • factor V Leiden
  • Factor V